簡単な血液検査で心疾患リスクをより正確に予測(Simple test could better predict your risk of heart disease)

ad

2025-04-28 チャルマース工科大学

チャルマース工科大学とハーバード大学の研究チームは、心疾患リスクをより正確に予測するための新しい血液検査法を開発した。従来のLDLコレステロール測定に代わり、アポリポプロテインB(apoB)とリポプロテイン(a)の2つのマーカーを測定することで、心疾患のリスクを高精度に評価できることを確認。特にapoBは「悪玉コレステロール」粒子の総数を示し、標準的なコレステロール検査では見逃されがちなリスクを捉えることが可能。研究は20万人以上のデータを分析し、15年間の追跡調査で検証された。これらのマーカーの測定は既に商業的に利用可能で、安価かつ簡便に導入できるとされる。

<関連情報>

ApoB含有リポ蛋白:数、タイプ、サイズ、および冠動脈疾患のリスク ApoB-containing lipoproteins: count, type, size, and risk of coronary artery disease

Jakub Morze , Giorgio E M Melloni , Clemens Wittenbecher , Mika Ala-Korpela , Andrzej Rynkiewicz , Marta Guasch-Ferré , Christian T Ruff , Frank B Hu , Marc S Sabatine , Nicholas A Marston
European Heart Journal  Published:28 April 2025
DOI:https://doi.org/10.1093/eurheartj/ehaf207

簡単な血液検査で心疾患リスクをより正確に予測(Simple test could better predict your risk of heart disease)
Structured Graphical Abstract

Abstract

Background and Aims

Apolipoprotein B concentration reflects the number of atherogenic lipoproteins and is recognized as a key lipid risk marker. Whether the type or size of apoB particle (apoB-P) adds predictive value for coronary artery disease (CAD) remains unclear.

Methods

A prospective analysis of 207 368 UK Biobank participants with comprehensive lipoprotein profiling and no prior history of atherosclerotic disease, diabetes, or active lipid-lowering therapy was conducted. Multivariable-adjusted Cox regression models were used to examine the association between each of the following lipid parameters with incident CAD: (i) nuclear magnetic resonance-measured apoB-P, (ii) concentrations of individual lipoprotein classes [very-low-density lipoprotein (VLDL), low-density lipoprotein (LDL)], (iii) size subclasses, (iv) average particle diameter, and (v) immunoassay-measured lipoprotein(a) [Lp(a)].

Results

A one standard deviation (SD) increase in apoB-P was associated with a 33% higher CAD risk [hazard ratio (HR): 1.33, 95% CI: 1.30–1.36]. Although VLDL particles were observed to carry a higher per-particle risk (HR per 100 nmol/L: 1.22, 1.11–1.34) compared with LDL (HR per 100 nmol/L: 1.07, 1.05–1.08), this difference was counterbalanced after considering relative particle abundance (LDL 91% vs VLDL 9% of total apoB-P). Thus the respective HR per 1-SD were 1.09 (1.05–1.14) and 1.24 (1.19–1.30). Particle diameter or size subclasses were not associated with CAD after apoB-P adjustment. The association of Lp(a) was robust even after apoB-P adjustment (HR:1.18, 1.16–1.20) and added independent prognostic value for CAD (area under curve: 0.769 vs 0.774, P < .001).

Conclusions

Lipid-related atherosclerotic risk is most accurately reflected by the total count of apoB-P and is largely unaffected by the major particle type (VLDL, LDL) or size. Elevated count of Lp(a) adds additional risk, and thus adequate assessment of atherogenic risk from dyslipidemia is best accomplished by consideration of both apoB-P and Lp(a) concentrations.

医療・健康
ad
ad
Follow
ad
タイトルとURLをコピーしました